FDA+ roundup: Flurry of guidance documents, updated risk criteria for Covid-19 mAbs, personnel moves and more
The FDA remains without a permanent commissioner but as acting commissioner Janet Woodcock told the Food and Drug Law Institute’s annual conference yesterday, nothing at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
